Cost per responder of TNF-α therapies in Germany

Tumor necrosis factor α (TNF-α) inhibitors ranked highest in German pharmaceutical expenditure in 2011. Their most important application is the treatment of rheumatoid arthritis (RA). Our objective is to analyze cost per responder of TNF-α inhibitors for RA from the German Statutory Health Insurance...

Descripción completa

Detalles Bibliográficos
Autores principales: Gissel, Christian, Repp, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2013
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544564/
https://www.ncbi.nlm.nih.gov/pubmed/23877487
http://dx.doi.org/10.1007/s10067-013-2332-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544564/
https://www.ncbi.nlm.nih.gov/pubmed/23877487
http://dx.doi.org/10.1007/s10067-013-2332-1

Ejemplares similares